Cure; ChatGPT
Overview
Increasingly the bet is to treat diseases the FDA already recognizes rather than aging itself, wagering that an approval now funds the broader goal of preventing disease later.
Longevity biotech has attracted billions of dollars from venture capital firms, governments, and some of Silicon Valley's biggest names. But the industry's most pressing business question remains unanswered: Can therapies built on aging biology become sustainable biotech companies?
Few people have spent more time trying to answer that question than James Peyer, the founder and CEO of longevity biotech company Cambrian Bio. He argues the field still hasn't broken what he calls its “glass ceiling.”
“The glass ceiling on the field that nobody has broken yet is: Can you take one of these drugs that is widely viewed as an invention of the geroscience field, something that would not have existed if not for this revolution in academic aging biology, and show human translatability with that medicine?” he said.
That question has become one of the defining challenges for longevity biotech. Investors increasingly believe the science deserves funding. What they're still waiting to see is whether aging biology can produce drugs, businesses, and returns that last.
The Glass Ceiling No One Has Broken
For years, researchers produced evidence that aging biology could be manipulated in animals. Between 2009 and 2015, they identified more than 15 agents that extended healthy lifespan and reduced frailty in mice. Peyer sees those discoveries as the foundation of the modern longevity industry.
“The actual novel observation, the new science that was driving that,” Peyer said, was that researchers “found ways to take these core pathways in cell biology and manipulate them in ways that pharma had never really done before.”
James Peyer; Courtesy of Cambrian Bio
Yet investors largely stayed on the sidelines. While the science was promising, the business model remained unclear. Peyer, however, believed investors were looking at the problem the wrong way.
Instead of trying to win approval for an anti-aging drug, he argues that longevity companies should first develop medicines for established disease indications before expanding into broader preventive uses.
Today, that strategy has increasingly become the industry's playbook.
Michelle Kwok, a principal at venture capital firm Draper Associates, whose investment portfolio includes frontier biotech companies, says investors now expect longevity startups to pair ambitious visions with practical clinical plans. “You have to go after an indication first, or else, how are you gonna get anything through the FDA?” she said.
Investor sentiment has shifted dramatically as well. “This is a much better funding environment for bio companies,” she said. “People are really understanding this long bio story now.”
“People who had told me they would never invest in bio are suddenly dipping their toes in, so arguably it's a better time than ever to be a long bio company," she added.
The shift toward disease-focused development may represent the industry's most important evolution, and could help it break the glass ceiling.
Charles Brenner, a professor of metabolic regulation at the University of Helsinki, says the industry still needs stronger proof.
He pointed out that many of the biggest successes discussed at longevity conferences today did not emerge directly from geroscience research. GLP-1 drugs, for example, began as treatments for diabetes before their effects on weight loss and other health outcomes became apparent.
“The intention of geroscience to specifically target a key pillar of aging and to get something that's better than medicine that was developed for disease and conditions, that's certainly not been demonstrated," Brenner said.
Still, he sees progress. Companies that once promoted broad anti-aging ambitions increasingly appear focused on specific diseases, measurable endpoints, and realistic clinical programs. Brenner described the shift as a growing sense of “sobriety" within the field.
Why Cambrian Chases Disease Before Aging
Before founding Cambrian Bio, Peyer launched Apollo Health Ventures in 2016, one of the earliest venture firms focused on longevity biotechnology. Eventually, though, he concluded that investing alone wasn't enough.
He was convinced that the field's biggest challenge was proving that promising discoveries in aging biology could survive clinical development.
“I want to stand at the driver's seat as we do that clinical development, not help build the boat at the pre-clinical stage,” Peyer said. That realization led him to found Cambrian Bio in 2019.
Rather than pursuing aging as a stand-alone indication, Cambrian focuses on diseases that regulators already understand and investors already fund.
For example, Cambrian’s lead drug, ATX-304 — the first AMPK Network Activator to enter clinical development — is being developed for obesity and cardiometabolic disease, not aging. Yet Peyer believes the metabolic pathways it targets, which decline universally with age, could ultimately address and prevent multiple chronic diseases tied to aging itself.
Peyer describes this approach as identifying “stepping stone indications” — diseases that provide a practical route into the market while preserving the possibility of broader preventive applications later.
The strategy recently produced one of the company's most significant milestones.
In June, Cambrian announced early Phase 1b human trial results for ATX-304. The company said participants burned more calories at rest and showed improvements in several markers of metabolic health, including liver fat, visceral fat, and triglycerides, while the drug's safety profile looked similar to a placebo.
“We actually presented what I think is the furthest-along evidence for this in the global pipeline,” Peyer said of the study’s findings.
Brenner, who has been critical of many longevity claims, called the early findings encouraging. “Increasing energy expenditure is a great target,” he said, agreeing that Cambrian's results represent a big win for the industry.
Legibility Beats the Science Deck
One of longevity biotech's biggest challenges isn't convincing investors that aging matters. It's convincing them that a company can survive long enough to prove its science.
Kwok says that at the earliest stages, investors already rely on scientific experts to evaluate the biology. What they're really assessing is whether founders can communicate a vision, build a business, and attract the people they'll need to succeed.
Many founders, she said, make the same mistake, which is assuming that the science will sell itself.
“Some people come with a 62-page science deck when we're first meeting,” Kwok said. “We're so deep in it that I don't even know where we are.” Even technically trained investors can lose the thread, she added, because no one specializes in every corner of biology.
Instead, she says founders should begin with a problem everyone can understand before diving into the science.
“I want to get rid of Alzheimer's forever,” she said, describing the kind of message that resonates with investors. The technical details can come later. “If a VC is lost in the first 5 minutes, you are never getting them back.”
The challenge, Kwok said, isn't simply proving the biology. “It really is making yourself as a company legible to any type of investor.”
The First Drug Won’t Be the Finish Line
Peyer doesn't expect the first successful longevity drug to transform medicine overnight. Instead, he sees it as the beginning of a much longer process, similar to what happened with HIV treatment.
In the early 1990s, HIV was widely considered a death sentence. The first antiretroviral drugs offered only modest gains, buying patients a few more years rather than curing the disease. But those additional years gave researchers time to develop better therapies, which eventually replaced the earlier drugs and transformed HIV into a manageable chronic condition.
"The first drug is gonna be great,” he said of the longevity industry. “But really if you go past 10 years and you look at 20 years or 30 years in the future, that first drug probably is not even in use.”
Rather than searching for a single anti-aging breakthrough in geroscience, the industry's real goal is creating a feedback loop in which each successful therapy creates enough momentum, investment, and scientific understanding to build the next generation of treatments.
That feedback loop isn't just a scientific ambition. It could become longevity biotech's sustainable business model, answering the question that has shadowed the industry for years: whether aging biology can support companies that endure as long as the therapies they hope to create.
For Peyer, that's the field's ultimate legacy: establishing preventive medicine as a lasting biotech category where each generation of therapies makes the next one possible.
